Intelligent bio solutions reports fiscal 2025 fourth quarter and full year results, highlighting progress on planned u.s. market expansion, revenue growth and increased operational efficiencies

Company advanced efforts to secure u.s. fda 510(k) clearance to advance on path towards planned u.s. market expansion beyond forensic use only settings

INBS Ratings Summary

INBS Quant Ranking